Now showing items 1-2 of 2

  • Fibulin-2: A Novel Biomarker for Differentiating Grade II from Grade I Meningiomas 

    Sofela, AA; Hilton, DA; Ammoun, S; Baiz, D; Adams, CL; Ercolano, E; Jenkinson, MD; Kurian, KM; Teo, M; Whitfield, PC; Sahm, F; Hanemann, CO (MDPI AG, 2021-01-08)
    <jats:p>There is an unmet need for the identification of biomarkers to aid in the diagnosis, clinical management, prognosis and follow-up of meningiomas. There is currently no consensus on the optimum management of WHO ...
  • Molecular and translational advances in meningiomas. 

    Suppiah, S; Nassiri, F; Bi, WL; Dunn, IF; Hanemann, CO; Horbinski, CM; Hashizume, R; James, CD; Mawrin, C; Noushmehr, H; Perry, A; Sahm, F; Sloan, A; Von Deimling, A; Wen, PY; Aldape, K; Zadeh, G; International Consortium on Meningiomas (England, 2019-01-14)
    Meningiomas are the most common primary intracranial neoplasm. The current World Health Organization (WHO) classification categorizes meningiomas based on histopathological features, but emerging molecular data demonstrate ...

All items in PEARL are protected by copyright law.
Author manuscripts deposited to comply with open access mandates are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.
Theme by 
@mire NV